Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibiotics | ||
By: PR Newswire Association LLC. - 14 Feb 2024 | Back to overview list |
|
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, and Zoetis, the world's leading animal health company, announced today a collaboration to discover and develop novel antibiotics for animal health. "According to authorities including the FDA, CDC, WHO, WOAH, and EMA, antibiotic resistance can spread between animals & humans and this is particularly devastating for antibiotics that are the last line of treatment for critical infections in people. Blacksmith and Zoetis will collaborate to discover and develop novel antibiotics to selectively target bacteria for animal health," said Zachary Zimmerman, Ph.D., CEO and co-founder of Blacksmith. "This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products." "As part of our commitment to reduce the dependency on antibiotic classes shared with human health, we are pleased to leverage our veterinary expertise along with our extensive collection of pathogens in this collaboration with Blacksmith," said Dr. Jeff Watts, Research Director, External Innovation at Zoetis. "Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock." About metalloenzymes and the Blacksmith platform Metalloenzymes utilize a metal ion cofactor in the enzyme active site to perform essential biological functions. This diverse class of targets has historically been difficult to drug due to small molecule chemistry limitations that have plagued the industry. The Blacksmith metalloenzyme platform has solved this problem by leveraging the following:
About Zoetis About Blacksmith Medicines Blacksmith has executed strategic drug discovery collaborations with Basilea Pharmaceutica International Ltd., Cyteir Therapeutics Inc., Eli Lilly and Company (Lilly), Hoffmann-La Roche Ltd., and Zoetis LLC., and has been awarded non-dilutive Federal funding agreements with CARB-X and NIH/NIAID. Blacksmith investors include Lilly, Evotec A.G., MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. For further information, please visit the company's website www.BlacksmithMedicines.com and LinkedIn. Media Contact: View original content to download multimedia:https://www.prnewswire.com/news-releases/blacksmith-medicines-and-zoetis-announce-research-collaboration-for-novel-animal-health-antibiotics-302061247.html SOURCE Blacksmith Medicines |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |